Lung Cancer Rx

Neoadjuvant Therapy for Early-Stage Lung Cancer: Where Do Things Stand, and What’s Next?

Given recent advances, where do things stand for neoadjuvant therapy in patients with NSCLC? The panel discusses current considerations and what important questions may soon be answered. Patrick Forde MBBCh, PhD, a thoracic medical oncologist at Johns Hopkins University in Baltimore, Maryland, and professor of immuno-oncology at Trinity College Dublin discusses current multidisciplinary approaches to perioperative care in NSCLC with Eric K. Singhi, MD, a thoracic oncologist in Houston, and Aakash Desai, MD, MPH, an assistant professor at the University of Alabama at Birmingham’s O’Neal Cancer Center.

Lung Cancer Myths: Separating Fact From Fiction

From screening to treatment, myths and misperceptions about lung cancer present challenges for physicians and patients. From setting the record straight on surgical approaches to setting higher expectations for treatment outcomes, the LungCancerRx panel tackles key questions currently faced in practice.

“Just Doesn’t Make Sense”: What’s Missing When It Comes to Diagnosing Lung Cancer

Despite notable recent advances in lung cancer treatment, early diagnosis remains a challenge. From problems with screening criteria to changes in disease demographics, the LungCancerRx panel explains why the only solution is “education, education, education.”

“We Want to Stop the Gatekeeping of Information”: The Origin of LungCancerRx

To cap off the first year of the LungCancerRx podcast, cohosts Aakash Desai, MD, MPH; Eric K. Singhi, MD; and Fawzi F. Abu Rous, MD, share how they first came together and what they see as their mission for the series moving forward. “I think we want to stop the gatekeeping of information,” Dr. Singhi explained.

“Absolute Flood” of ADCs and Key Data Lead to “Good Challenges” in EGFR-Mutated NSCLC

In this episode of LungCancerRx, Eric Singhi, MD, Aakash Desai, MD, MPH, and Fawzi F. Abu Rous, MD, welcome Julia Rotow, MD to the conversation. “I think we’ve been very lucky, in the world of EGFR-mutated lung cancer, that it has gotten so complicated,” explains Julia Rotow, MD [https://www.dana-farber.org/find-a-doctor/julia-rotow], clinical director of the Lowe Center for Thoracic Oncology and director of clinical research at the Dana-Farber Cancer Institute in Boston. Dr. Rotow explains how key data from the HARMONi [https://www.smmttx.com/clinical-trials/harmoni-clinical-trial/], COMPEL [https://www.clinicaltrials.gov/study/NCT04765059], and MARIPOSA-2 [https://www.clinicaltrials.gov/study/NCT04988295] studies and a wave of new treatment options on the horizon have led to “good challenges” in non-small cell lung cancer care.